The appointment will enable SmartPharm Therapeutics to expand its expertise pool and advance its offerings.
FREMONT, CA: SmartPharm Therapeutics, a preclinical-stage pharmaceutical company specializing in the development of advanced, non-viral gene therapies for rare disease treatment, recently appointed Fred Driscoll to its Board of Directors, expanding its knowledge base with 40 years of expertise in finance and corporate strategy for the biotechnology industry.
Driscoll possesses deep experience in the biotechnology sector and has successfully launched high-value programs, formed robust teams, and developed strategic alliances. The contributions and expertise of Driscoll will potentially prove invaluable to the company in advancing their development programs.
He showed his excitement in joining the company, commending its innovative and proprietary platform technology. The product has broad applicability, primarily for enzyme replacement therapy and rare disease treatment, including additional areas such as tissue restoration and cancer biologics. Driscoll can bolster the novel pipeline of non-viral gene-encoded protein therapies developed by SmartPharm’s collaborative and inspired team of professionals with his expertise in the area.
Driscoll had served as the CFO at Flexion Therapeutics before his retirement in the year 2017, where he led a successful IPO in the year 2014. He raised over $600 million in tenure toward the FDA approval for Zilretta. From years 2009 to 2013, Driscoll worked as a CFO for Novavax, a publicly-traded biopharmaceutical company. Before that, he served at Genelabs Technologies as a CFO from 2007 to 2008, and as a CEO from 2008 to 2009. He also served as a CEO at the biopharmaceutical company OXiGENE from 2000 to 2006.
He earned a Bachelor’s degree in Accounting and Finance from Bentley University. His career in the biotechnology sector began at Instrumentation Laboratory, an in vitro diagnostics company, where he served as a CFO. He was also a Chairman of the Board at OXiGENE and a member of the audit committee for Cynapsus Therapeutics. Currently, he is on the boards of Cellectar Biosciences, Cue Biopharma, MEI Pharma, and NantKwest.
SmartPharm develops robust gene therapies with its vision of biologics from within. It is currently focusing on the development of new pipelines for non-viral, gene-encoded proteins for the treatment of conditions requiring enzyme replacement therapy and tissue restoration.